Dr. Jackson on Benefits of Maintenance Therapy for Myeloma

Graham Jackson, MD, PhD
Published: Tuesday, Jan 17, 2017



Graham Jackson, MD, PhD, Northern Institute for Cancer Research, Newcastle University, discusses the benefits of maintenance therapy for patients with multiple myeloma.

Eight-hundred fifty-seven patients in the study went on to receive lenalidomide (Revlimid) maintenance. It’s safe and deliverable while prolonging remission for most subgroups of patients, such as transplant eligible patients and the patients that are older, frailer, and not eligible for a transplant, explains Jackson.

Although there have been instances of malignancies, it has been shown that the secondary malignancies are not as serious as previously thought.
 
SELECTED
LANGUAGE


Graham Jackson, MD, PhD, Northern Institute for Cancer Research, Newcastle University, discusses the benefits of maintenance therapy for patients with multiple myeloma.

Eight-hundred fifty-seven patients in the study went on to receive lenalidomide (Revlimid) maintenance. It’s safe and deliverable while prolonging remission for most subgroups of patients, such as transplant eligible patients and the patients that are older, frailer, and not eligible for a transplant, explains Jackson.

Although there have been instances of malignancies, it has been shown that the secondary malignancies are not as serious as previously thought.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x